The regulatory label is the valuation

Among diagnostics and reagent businesses, the regulatory posture of the product portfolio determines the buyer universe, the margin profile and the risk allocation in a transaction. It is frequently a larger driver of value than revenue growth, and it is the area where owner expectations and acquirer views diverge most sharply.

Three labels, three assets

A research use only product sells into research budgets. The sales cycle is short, there is no regulatory submission behind it, and the claims that can be made are correspondingly limited. It is a good business, and it is valued as a research tools business.

An analyte specific reagent occupies a narrower category with its own restrictions, generally sold to clinical laboratories that build their own tests around it.

An in vitro diagnostic carries a cleared or approved claim. It sells into clinical budgets, it has been through a submission that a competitor would also have to complete, and once written into a laboratory’s standard operating procedure it is difficult to displace. The gap between an RUO business and an IVD business in multiple terms is substantial, and the path from one to the other is expensive, slow, and not guaranteed.

The exposure that surfaces in diligence

The common and consequential finding is the product labelled for research that everyone in the value chain knows is being used clinically. It arises honestly. A laboratory validates an RUO reagent into a laboratory developed test, volumes grow, and the manufacturer continues to ship against a label that no longer describes the use.

A buyer’s regulatory counsel will find this. When they do, the question is not whether the revenue is real but who carries the liability, and the answer is that it follows the asset. The practical outcomes are an indemnity, an escrow, a price adjustment, or in some cases a buyer withdrawing altogether because the exposure cannot be quantified within the timetable.

Preparing the position

None of this is an argument against selling such a business. It is an argument for establishing the position before a buyer does.

That means knowing, by product and by customer, what the labelled use is and what the actual use is; having taken regulatory advice on the gap; and having a documented view of what remediation would cost and how long it would take. A seller who can hand that analysis over on day one is negotiating about a known and bounded issue. A seller who cannot is negotiating about an unknown one, and unknowns are priced at the pessimistic end.